GLP1R and atherosclerosis: Although the first-line medication for type 2 diabetes is metformin, glucagon-like peptide-1 receptor agonists (GLP-1RAs) along with sodium–glucose cotransporter 2 inhibitors (SGLT2is) are recommended for patients with established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors [6, 7].